BridgeBio Pharma Reports Strong Q3 2026 Revenue Growth Driven by Attruby Expansion
BridgeBio Pharma (BBIO) reported a significant revenue increase to $353.2 million for the third quarter of 2026, up from $120.7 million in the same period last year. This growth was primarily fueled by the Attruby franchise, which saw U.S. revenue reach $253.3 million (a 134% year-over-year increase), and a one-time $75 million milestone payment from Bayer related to BEYONNTRA sales in Europe. The company's financial position has strengthened significantly, reporting its strongest cash position in history at $1.5 billion. While the company continues to operate at a loss due to heavy R&D and commercialization investments, operating losses improved drastically compared to the prior year. Management is now shifting focus toward an execution phase involving three upcoming product launches, including BBP-418, which has a PDUFA date set for November 27, 2026.
Topics: Cash Position Operating Loss Improvement Pharmaceuticals Product Launch Revenue Growth